Evotec, Apeiron ink cancer immunotherapy agreement
HAMBURG, Germany—Evotec AG has announced a research collaboration with Apeiron Biologics to develop immunomodulatory lead compounds for treating cancer. Apeiron Biologics will bring to the table its expertise in in-vitro and in-vivo pharmacology, while Evotec will handle the medicinal chemistry and chemical proteomics. No financial terms for the partnership were disclosed. The collaboration results from the success of a phenotypic high-throughput screen commissioned by Apeiron Biologics to Evotec.
"We were excited about the outcome of the primary screen and look forward to refining the hit compounds in this collaboration applying our immunological know-how. There is no doubt that immunomodulatory compounds like these carry huge therapeutic and commercial potential," Dr. Hans Loibner, CEO of Apeiron Biologics, said in a press release.